Table 3 Levels of the VIRMs in IVR group and IVA group.
Ranibuzumab | Aflibercept | ||||||
|---|---|---|---|---|---|---|---|
pre | 1w | 1M | pre | 1w | 1M | ||
cardiac toroponin (pg/ml) | AC | 56.5 ± 11.9 | 66.1 ± 17.3 | 58.4 ± 14.3 | 60.7 ± 16.7 | ||
Plasma | 45.6 ± 14.5 | 53.1 ± 15.1 | 63.2 ± 19.7 | 38.9 ± 12.3 | 48.8 ± 14.0 | 52.2 ± 17.0 | |
ICAM1 (pg/ml) | AC | 2.7 ± 0.8 | 2.7 ± 1.0 | 3.7 ± 0.9 | 3.1 ± 0.7 | ||
Plasma | 517.7 ± 94.8 | 518.6 ± 95.9 | 538.9 ± 111.5 | 483.9 ± 60.6 | 451.7 ± 53.0 | 462.1 ± 55.3 | |
IL-6 (pg/ml) | AC | 8.1 ± 1.0 | 7.6 ± 1.2 | 10.2 ± 1.2 | 12.1 ± 2.3 | ||
Plasma | 7.2 ± 1.7 | 5.6 ± 1.2 | 3.4 ± 0.5 | 6.3 ± 1.8 | 5.6 ± 1.4 | 6.5 ± 1.7 | |
MCP-1 (pg/ml) | AC | 673.0 ± 60.1 | 688.9 ± 80.1 | 815.6 ± 61.8 | 894.0 ± 72.8 | ||
Plasma | 298.6 ± 17.2 | 308.8 ± 20.0 | 353.2 ± 31.5 | 354.0 ± 25.0 | 360.7 ± 34.6 | 360.8 ± 37.4 | |
MMP-8 | AC (pg/ml) | 125.0 ± 20.8 | 95.8 ± 24.5 | 147.0 ± 31.1 | 146.1 ± 31.5 | ||
Plasma(ng/ml) | 3.5 ± 0.6 | 2.7 ± 0.3 | 3.4 ± 0.7 | 3.2 ± 0.5 | 3.0 ± 0.6 | 3.6 ± 1.0 | |
TIMP-1 | AC(ng/ml) | 24.2 ± 3.0 | 22.0 ± 3.0 | 28.4 ± 2.8 | 33.2 ± 3.6 | ||
Plasma(ng/ml) | 102.0 ± 127.8 | 110.2 ± 13.2 | 93.1 ± 16.0 | 93.8 ± 10.1 | 90.2 ± 9.5 | 94.2 ± 10.7 | |
VCAM-1 | AC (pg/ml) | 37.9 ± 6.4 | 34.4 ± 6.0 | 46.1 ± 6.0 | 47.6 ± 7.0 | ||
Plasma(ng/ml) | 1.2 ± 0.1 | 1.2 ± 0.1 | 1.2 ± 0.1 | 1.4 ± 0.1 | 1.3 ± 0.1 | 1.3 ± 1.0 | |
cardiac myogrobin | AC (pg/ml) | 385.4 ± 199.8 | 220.1 ± 67.3 | 349.0 ± 75.2 | 336.8 ± 64.6 | ||
Plasma(ng/ml) | 9.4 ± 1.2 | 9.5 ± 1.6 | 10.3 ± 1.4 | 9.1 ± 1.0 | 7.8 ± 9.9 | 8.4 ± 9.0 | |
tenaacin-C | AC (pg/ml) | 256.8 ± 41.3 | 241.6 ± 53.0 | 364.6 ± 59.9 | 366.5 ± 62.8 | ||
Plasma(ng/ml) | 13.7 ± 5.8 | 13.5 ± 0.6 | 13.1 ± 8.3 | 13.3 ± 4.5 | 12.9 ± 4.6 | 13.1 ± 5.0 | |
TSP-2 | AC (pg/ml) | 564.3 ± 93.2 | 502.2 ± 111.6 | 696.4 ± 95.6 | 653.9 ± 99.8 | ||
Plasma(ng/ml) | 265.4 ± 30.2 | 263.0 ± 28.3 | 264.3 ± 30.4 | 269.7 ± 29.2 | 266.1 ± 26.6 | 278.6 ± 23.6 | |
